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ABSTRACT
Introduction: Little research to date has
examined antihyperglycemic agent (AHA)
utilization among patients with type 2
diabetes mellitus (T2DM) around transitions of
care from inpatient to outpatient settings.
Discontinuity of care between inpatient and
outpatient settings has been associated with
adverse clinical outcomes, so a better
understanding of AHA treatment patterns is
important.
Methods: This retrospective study assessed AHA
utilization among a sample of United States
adults with a T2DM diagnosis listed on an
inpatient admission during 2010–2012 in the
MarketScan Hospital Drug database (Truven
Health Analytics). AHA use while hospitalized
was measured from inpatient medication
administration records in that database. AHA
use pre- and post-hospitalization was assessed
from outpatient retail and mail order pharmacy
claims in the MarketScan Commercial and
Medicare Supplemental databases, which
contain de-identified insurance claims from
large employers and health plans. The hospital
and claims databases are linked, allowing
patients to be followed across transitions of
care.
Results: The study sample (N = 8144) was 53%
male, with a mean age of 66 years. Twenty-one
percent had no T2DM diagnosis or claims for
AHAs in the 90-day pre-hospitalization period
suggesting they may have been newly
diagnosed at the time of admission. Most
(83%) patients used AHAs while hospitalized,
but the proportions with AHA claims 30 days
pre- and post-hospitalization were only 53%
and 40%, respectively. Biguanides and
sulfonylureas were the most common
outpatient agents. Most (70%) patients who
had no AHA utilization pre-hospitalization
continued to have no AHA utilization
post-hospitalization. About half the patients
with AHA claims pre-hospitalization did not
have any AHA claims post-discharge.
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Conclusion: Further research is warranted to
explore the reasons why AHAs are not
continued following hospital discharge.
Inadequate treatment of T2DM remains an
issue before and after hospitalization; inpatient
stays represent an important and frequently
missed opportunity to assess and optimize care
for these patients.
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INTRODUCTION
In the United States (US), the goal of optimizing
treatment strategies for type 2 diabetes mellitus
(T2DM) has grown in urgency with the
epidemic rise of the disease. In 2012, an
estimated 9.3% of the US population had
diabetes, compared to 8.3% in 2010 [1]. The
number of hospitalizations each year among
people with diabetes also has risen
substantially, from 2.8 million in 1988 to
nearly 5.5 million in 2009 [2]. Previous
research has suggested that discontinuity of
care from the inpatient to the outpatient setting
is common, with perhaps as many of 42% of
patients discharged on medication not
reporting that medication regimen to
subsequent outpatient providers [3].
Current treatment guidelines recommend
the use of insulin as the preferred treatment
for hyperglycemia in the hospital setting, and as
a result, hospitalized patients with T2DM often
have the other antihyperglycemic agents
(AHAs) held and insulin initiated [4].
However, it remains unclear how hospitalized
patients transitioning to outpatient care are
being treated following discharge. Whether
patients receiving oral AHAs/glucagon-like
peptide-1 receptor agonists (GLP-1s) prior to
hospitalization resume their use, and whether
patients who were undiagnosed or untreated
before their hospitalization begin
antihyperglycemic therapy after discharge,
have been poorly studied. With the
tremendous increase in diabetes and focus on
linking continuity of care with adverse clinical
outcomes, it is imperative to better understand
which therapeutic strategies may lead to the
best outcomes for patients with T2DM.
Determining current treatment patterns
around transitions of care represents the first
step toward optimizing therapy across
treatment settings.
To assess AHA utilization patterns around
inpatient to outpatient transitions of care, we
conducted a retrospective database study
among a sample of US adults hospitalized with
a diagnosis of T2DM during 2010–2012.
METHODS
This study was a retrospective analysis of
de-identified medical and pharmacy data from
the 2010–2012 MarketScan Hospital Drug,
Commercial, and Medicare Supplemental
databases (Truven Health Analytics). The
Hospital Drug database is derived from
hospital ordering and billing systems, and
includes diagnosis and drug administration
information from inpatient settings in 659
acute-care US hospitals. The Commercial
database includes inpatient, outpatient, and
outpatient prescription drug claims for
commercially insured employees and their
dependents, covered under a variety of
fee-for-service and managed care health plans
through over 100 large employers and health
plans located across the US. The Medicare
92 Diabetes Ther (2016) 7:91–103
Supplemental database contains the healthcare
experience of retirees with Medicare
supplemental insurance paid for by a subset of
employers. Over 55,000 hospital discharges in
the 2010–2012 Hospital Drug database can be
linked to claims in the Commercial and
Medicare Supplemental databases, and served
as the basis of this study that followed patients
across outpatient and inpatient settings of care.
Patients selected for the study were required
to meet the following criteria: (1)
hospitalization recorded in the linked Hospital
Drug database between January 1, 2010 and
December 31, 2012 with a T2DM diagnosis code
[International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9) 250.x0,
250.x2] listed in any diagnosis field, the earliest
of which represented the index hospitalization;
(2) available data in linked claims for a period of
90 continuous days before the index
hospitalization admission date and 90 days
after the index hospitalization discharge date;
and (3) age 18 years or above on the index
hospitalization admission date. Patients with
any claims of ketoacidosis in the 90 days before
the index hospitalization admission date,
during the index hospitalization, or in the
90 days after the index hospitalization
discharge date were excluded from the study.
This exclusion was intended to help ensure
patients with type 1 diabetes miscoded as type 2
on the index hospitalization were not part of
the study sample. Although ketoacidosis can
occur in T2DM, it is more often associated with
type 1 diabetes [4].
AHA utilization was the key outcome
measured in this study and was assessed
before, during, and after the index
hospitalization. Pre-hospitalization AHA
utilization was based on retail outpatient
pharmacy claims 30 days pre-admission, and
mail order pharmacy claims 90 days
pre-admission (including the date of
admission). This time period was selected
because retail pharmacy prescriptions typically
cover up to 1 month of therapy while mail order
prescriptions may cover up to 3 months of
therapy. Therefore, AHA claims in this time
window were likely to represent AHA therapy as
of the time of admission. Retail pharmacy
claims also were assessed during 60 and
90 days pre-admission to assess the sensitivity
of the primary pre-index measure. AHA
utilization during the index hospitalization
was derived from inpatient medication
administration data from the date of
admission through the date of discharge.
Post-hospitalization AHA utilization was based
on retail and mail order outpatient pharmacy
claims on the date of discharge and the
subsequent 30 days. This time period was
selected because the intent was to capture
prescriptions filled shortly after discharge,
which were most likely to represent any
regimen changes that occurred as a result of
hospitalization. However, because some
patients may have had a pre-admission supply
of medication that they continued to use
post-discharge, AHA claims over 60 and
90 days after discharge also were measured.
Within each time period, binary variables were
created to record patients’ AHA utilization at
the class level (e.g., biguanides, sulfonylureas)
and overall (i.e., any agent). In addition,
medication utilization was categorized as
insulin only (without oral AHAs or GLP-1), or
one, two, or three oral AHAs/GLP-1s with or
without insulin.
Other information recorded for patients at
the time of index admission included age,
gender, health plan type, and geographic
region. Additional variables measured during
the 90-day pre-hospitalization period included
Deyo Charlson Comorbidity Index (CCI) score
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[5], and selected comorbidities and
concomitant medications (displayed in
Table 1).
The primary diagnosis on the index
admission was used as the reason for
admission. Diagnoses that were glycemic
(hyperglycemia, non-ketotic hyperosmolar
coma, hypoglycemia), microvascular
(nephropathy, retinopathy, neuropathy, or
foot ulcer), or macrovascular (cardiovascular,
including atherosclerosis, myocardial
infarction, ischemic heart disease, heart
failure, stroke, or transient ischemic attack) in
nature were flagged because of their potential
relatedness to diabetes. Other primary diagnosis
codes were grouped at the three-digit ICD-9
Table 1 Patient demographic proﬁle and baseline clinical characteristics
Characteristics Study patients (N5 8144)
N/mean %/SD
Age, years (mean, SD) 66.2 13.2
Male (N, %) 4334 53.2%
Top 3 health plan types (N, %)
PPO 3076 37.8%
Comprehensive 3002 36.9%
POS plan 726 8.9%
Geographic region (N, %)
Northeast 68 0.8%




No T2DM medical or prescription claim in 90 days pre-index (N, %) 1708 21.0%
Baseline period Deyo-CCI (mean, SD) 1.6 1.8
Baseline presence of comorbid conditions (N, %)
Cardiovascular disease 2419 29.7%
Diabetic peripheral neuropathy or foot ulcer 694 8.5%
Diabetic retinopathy 336 4.1%
Diabetic nephropathy 253 3.1%
Concomitant medications (N, %)
Antihyperlipidemic medications 4153 51.0%
Antihypertensive medications 5139 63.1%
Antiobesity medications 10 0.1%
Deyo-CCI Deyo Charlson Comorbidity Index, POS Point of service, PPO Preferred provider organization, SD standard
deviation, T2DM type 2 diabetes mellitus
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code level to identify the top other reasons for
admission among the study sample. The length
of the index hospitalization and discharge
status were also recorded.
The presence of hypoglycemia or
hyperglycemia during the index admission was
measured using relevant primary or secondary
diagnosis codes listed on the index admission.
Because hypoglycemia may be poorly coded on
claims, in addition to hypoglycemia diagnosis
codes, other diagnoses that may be indicative of
the condition [e.g., ICD-9 249.30, 250.30
(diabetic coma) and 962.3 (poisoning by
insulin)] also were used to identify
hypoglycemia in accordance with a published
algorithm [6]. Diagnoses of uncontrolled
diabetes, diabetes with hyperosmolarity and
abnormal glucose were defined as
hyperglycemia.
All variables were tabulated for descriptive
review. Frequencies and percentages were
calculated for categorical variables and means
and standard deviations were examined for
continuous variables. Descriptive analysis was
undertaken to compare medication use before,
during and after hospitalization.
The study described in this paper was an
analysis of de-identified data and did not entail
primary research with human or animal
subjects. As such, institutional review board





A total of 9580 patients with T2DM were
identified in the data source, and 85%
(N = 8144) met all inclusion criteria for the
study. Study-eligible patients had a mean age of
66 years and 53% were male. Twenty-one
percent had no T2DM diagnosis or claims for
AHAs in the prior 90 days (Table 1). See Table 1
for complete demographics and clinical
characteristics.
Index Admission Characteristics
The hospitals in which the index admission
occurred tended to be medium (200–499 beds,
57%) or large-sized (500? beds, 30%). Most
were non-teaching hospitals (97%) located in
urban areas (85%).
A primary or secondary diagnosis of T2DM
was required on the index hospitalization for
study inclusion, but the primary reason for
admission was not diabetes related for most
patients in the study sample (Table 2). Only 3%
of patients had T2DM (ICD-9 250.x0, 250.x2)
listed as the primary diagnosis on their index
hospitalization. Twenty-two percent of patients
had a primary diagnosis potentially related to
diabetes, most of whom had a primary diagnosis
of a macrovascular-related condition (21%); few
patients had glycemic-related (\1%) or
microvascular-related (\1%) conditions.
Examination of other primary diagnoses
revealed a wide variety of conditions, with no
particular one predominating. The most
common primary diagnoses are shown in
Table 2 and included osteoarthritis (6%),
cardiac dysrhythmias (4%), and pneumonia
(3%).
Length of stay averaged 4.2 days (median
3 days; range 1–89 days). Most patients were
discharged home, but 10% were transferred to
another facility (e.g., long-term care, skilled
nursing).
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AHA Utilization
Almost half (47%) of patients with T2DM did
not have any AHA claims in the 30 days prior to
hospitalization, and this proportion rose to
about 60% in the 30 days following discharge
(Table 3). Seventeen percent of patients had no
AHA utilization while in the hospital.
Biguanides (i.e., metformin) were the most
commonly filled oral AHAs pre- and
post-hospitalization, followed by the
sulfonylureas and dipeptidyl peptidase-4
(DPP-4) inhibitors (Fig. 1). Although only
about 15% of patients utilized insulin pre- or
post-hospitalization, insulin was utilized by the
majority of patients (71%) during
hospitalization.
Patients who did not have a claim for AHAs
before their hospitalization were unlikely to
have one afterward, and patients who had a
claim for AHAs before hospitalization often
discontinued them following discharge. Of the
patients without AHA claims in the 30 days
before their hospitalization, 70% continued to
Table 2 Characteristics of the index hospitalization
Characteristics Study patients (N5 8144)
N/Mean %/SD
Primary diagnosis (N, %)
T2DM 271 3.3%
Glycemic related 57 0.7%
Microvascular related 66 0.8%
Macrovascular related 1704 20.9%
Top ﬁve other primary diagnoses (N, %)
ICD-9 715 Osteoarthrosis 474 5.8%
ICD-9 427 Cardiac dysrhythmias 322 4.0%
ICD-9 486 Pneumonia, organism unspeciﬁed 213 2.6%
ICD-9 786 Respiratory system/other chest symptoms 192 2.4%
ICD-9 038 Septicemia 189 2.3%
Hypoglycemia at index admission (N, %) 177 2.2%
Hyperglycemia at index admission (N, %) 898 11.0%
Length of index hospitalization, days (mean, SD) 4.2 4.0
Discharge status (N, %)
Discharged home 6948 85.3%
Transferred to another facility 848 10.4%
Other/Unknown 348 4.3%
ICD-9 International Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation, SD standard deviation, T2DM type 2
diabetes mellitus
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have no AHA claims in the 30 days after leaving
the hospital (Fig. 2). Approximately, half of the
patients who did have an AHA claim before
admission did not have any AHA claims in the
30 days post-discharge. The majority (55%) of
patients who were administered AHAs during
hospitalization had no AHA claims after leaving
the hospital (Fig. 3).
A subgroup analysis that assessed AHA
claims among patients with no T2DM
diagnosis or claims for AHAs in the 90 days
pre-admission (N = 1708) revealed that 77% of







N % N % N %
AHAsa
Biguanides 2103 25.8 1999 24.5 1408 17.3
Sulfonylureas 1526 18.7 1786 21.9 1051 12.9
Insulins 1302 16.0 5739 70.5 1206 14.
DPP-4 inhibitors 599 7.4 593 7.3 400 4.9
Thiazolidinediones 585 7.2 568 7.0 312 3.8
Otherb 146 1.8 42 0.5 80 1.0
Type of AHA regimen
No AHAs 3846 47.2 1376 16.9 4846 59.5
Insulin only (no oral agent or GLP-1) 824 10.1 3135 38.5 823 10.1
1 oral agent/GLP-1 ± insulin(s) 2139 26.3 2395 29.4 1742 21.4
With insulin 304 3.7 1689 20.7 281 3.5
Without insulin 1835 22.5 706 8.7 1461 17.9
2 oral agents/GLP-1s ± insulin(s) 1053 12.9 986 12.1 601 7.4
With insulin 146 1.8 732 9.0 85 1.0
Without insulin 907 11.1 254 3.1 516 6.3
3 oral agents/GLP-1s ± insulin(s) 282 3.5 252 3.1 132 1.6
With insulin 28 0.3 183 2.2 17 0.2
Without insulin 254 3.1 69 0.8 115 1.4
AHA antihyperglycemic agent, DPP-4 dipeptidyl peptidase-4. GLP-1 glucagon-like peptide-1 receptor agonist
a Patients may use more than one AHA during an observation period; therefore the sum of the percentages may be greater
than 100%
b ‘Other’ consists of the following AHA classes; alpha-glucosidase inhibitors, amylin analogs, bile acid sequestrants,
dopamine receptor agonists, GLP-1 agonists, and meglitinides; all of which had little utilization (\2%) during the three
observation periods
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these patients had no AHA claims in the 30 days
after discharge. The corresponding rate among
patients with evidence of either T2DM
diagnoses or AHA claims pre-admission
(N = 6436) was 55%. In another subgroup
analysis among patients whose index
Fig. 1 Most common antihyperglycemic agents pre-, during, and 30 days post-hospitalization in patients with
pre-hospitalization utilization of any antihyperglycemic agent (n = 4298). DPP-4 dipeptidyl peptidase-4
Fig. 2 Changes in AHAs from pre- to 30 days post-hospitalization—all patients (n = 8144). Asterisks with or without
insulins. AHA Antihyperglycemic agent, GLP-1 Glucagon-like peptide-1 receptor agonist
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admission diagnosis was T2DM (N = 271), 61%
of patients had an AHA claim following
discharge, compared to 40% among patients
whose hospitalization had a non-T2DM primary
diagnosis (N = 7873).
In the 60- and 90-day pre- and
post-hospitalization analysis, the proportion of
patients with no AHA utilization decreased as
the follow-up period increased (Table 4). In the
90 days pre-admission, 35% of patients had no
AHA claims, compared to 47% over 30 days
pre-admission. The corresponding
post-discharge rates were 35% with no AHA
claims over 90 days and 60% over 30 days. No
AHA claims either pre-admission or
post-discharge were observed among 24% of
the sample over 90 days, compared to 35% over
30 days.
DISCUSSION
The results of this retrospective study of
hospitalized adults with T2DM suggest
patients may not be receiving optimal AHA
therapy during transitions of care around the
time of hospitalization. Most patients (83%)
received AHAs while hospitalized, but
approximately half had no AHA claims in the
30 days prior to hospitalization (90 days for
mail order) and about 60% had no AHA claims
in the 30 days post-discharge. Lengthening the
pre- and post-hospitalization periods reduced
the proportion of patients without AHA claims
but one-third of patients still had no AHA claim
before and after the hospital stay even with a
longer 90-day window. Patients who did not
have AHAs claims before hospitalization were
Fig. 3 Changes in AHAs during hospitalization to 30 days post-hospitalization—all patients (n = 8144). Asterisks with or
without insulins. AHA Antihyperglycemic agent, GLP-1 Glucagon-like peptide-1 receptor agonist
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unlikely to start afterward, and a large
proportion of patients who utilized AHAs
pre-admission or during their stay often
discontinued these medications upon
discharge. This is concerning because lack of
continuity of care has been associated with
adverse clinical outcomes, especially in patients
with a chronic condition [3]. In a study of
Medicare beneficiaries with diabetes
hospitalized for acute myocardial infarction,
for example, patients discharged without AHA
therapy had higher mortality rates 30 days,
6 months, and 1 year post-hospitalization than
patients discharged on AHA therapy, even after
multivariable adjustment of differences
between groups [7].
It deserves mention that although all
patients in the study had a primary or
secondary diagnosis of T2DM during the index
hospitalization, 21% percent of patients in this
study had no healthcare claims with a T2DM
diagnosis and no pharmacy claims for AHAs in
90 days prior to their index hospitalization.
Specific clinical details on these patients were
not available in the database used for the
analysis, but these patients may represent
previously undiagnosed patients whose T2DM
was initially identified during the index
admission. It also is possible they were
diagnosed patients treated with lifestyle
interventions alone (e.g., diet and exercise but
no AHA) who did not incur any healthcare
services carrying a T2DM diagnosis in the 90
days prior to hospitalization. These patients had
the lowest rates of post-discharge AHA claims
but subgroup analyses excluding them entirely
did not drastically alter study results; 60% of all
patients had no AHA claims in the 30 days
post-discharge whereas after this exclusion,
55% of the remaining patients had no AHA
claims in the 30 days post-discharge.
Our study finding that 60% of all patients
with T2DM had no AHA claims in the 30 days
post-discharge (corresponding figures for 60 and
90 days post-discharge were 44, and 35%,
respectively) while high, was in line with the
small body of previous research examining
post-discharge AHA treatment patterns. Wu
et al. [8] studied 2160 patients with T2DM
who used insulin both in the 30 days before and
during hospitalization, identified through
retrospective medical records review at a US
health system, and found 61% discontinued
insulin upon discharge. About 60% of these














Proportion of patients, by AHA regimen
No AHAs 47.2 39.4 35.0 59.5 43.4 35.4
Insulin only (no oral agent or GLP-1) 10.1 12.0 14.5 10.1 13.0 12.5
1 oral agent/GLP-1 ± insulin(s) 26.3 29.5 30.8 21.4 28.2 30.7
2 oral agents/GLP-1s ± insulin(s) 12.9 14.8 15.0 7.4 12.1 16.5
3 oral agents/GLP-1s ± insulin(s) 3.5 4.3 4.7 1.6 3.3 4.8
AHA antihyperglycemic agent, GLP-1 glucagon-like peptide-1 receptor agonist
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patients were also treated with oral AHAs in the
6 months before hospitalization, but only about
20–25% were treated with oral AHAs in the
60 days post-discharge. Bergenstal et al. [9]
assessed pre- and post-admission treatment
patterns in a retrospective database analysis of
400 patients, and found 24% had a reduction in
AHA regimen after hospitalization. Lipska et al.
[7] found that 13.4% of 8791 Medicare patients
on AHA therapy at the time of admission for
acute myocardial infarction were discharged
without such therapy, according to medical
record review conducted as part of the National
Heart Care Project. In a retrospective
chart review of 217 diabetic patients admitted
with acute myocardial infarction, Lovig et al.
[10] found 11.5% of these patients were
discharged without any AHAs, despite most
having no clinical reason to discontinue AHAs.
Griffith et al. [11] retrospectively examined
1359 men with poorly controlled diabetes
(HbA1c [8.0%) discharged from Veterans’
Administration hospitals and found less than
one quarter had a change in therapy upon
discharge, and almost one-third had no change
in therapy or scheduled follow-up for
continuing care within 30 days. The authors
suggest that this lack of treatment modification
or follow-up care despite evidence of poorly
controlled disease may reflect ‘clinical inertia.’
An alternate explanation to ‘clinical inertia’
is that there was a deliberate decision to not
utilize AHAs post-hospitalization. While the
data used in this study did not allow
examination of clinical decision making,
lifestyle interventions alone may be
appropriate initial treatment for T2DM [4] and
survey data suggests about 14% of US adult
diabetes patients do not use AHAs, [1] so not all
patients in our sample were expected to have
AHA utilization post-discharge. In addition,
some patients in our study may have had
non-diabetes-related elevated glucose levels
during hospitalization that resulted in an
erroneous T2DM diagnosis on their hospital
record; any such patients may not have required
AHA utilization post-discharge. It is notable,
though, that Loving and colleagues [10]
conducted medical chart review to assess
reasons for AHA discontinuation among
diabetic patients hospitalized for myocardial
infarction and were unable to find a clear
reason for discontinuation for 88% of patients.
That, along with the high proportion of
patients with no post-hospitalization AHA in
the current and previous studies, suggests
hospitalization may not result in an
appropriate re-evaluation of therapy. This may
be problematic, as patients with T2DM who are
hospitalized tend to have poorer glycemic
control than comparable patients who are not
hospitalized, and the hospitalization may
present an opportunity to intervene [12].
Other literature has suggested that a hospital
admission may allow an opportunity to
improve long-term diabetes care [13].
We measured AHA pre- and
post-hospitalization utilization based on
outpatient pharmacy claims, leaving open the
possibility that patients may have received
AHAs that do not appear in the data. For
example, it is possible that some patients
received samples, paid cash for low-cost
generic AHA prescriptions such that no claim
was generated to their health plan, or had a
pre-admission supply of medication that they
utilized post-discharge, all of which could make
it appear as if patients had no AHA utilization
when, in fact, they did use AHAs post-discharge.
In addition, inpatient medication utilization for
readmitted patients (12% within 30 days; 21%
within 90 days) was not captured in our
post-discharge medication utilization
measures. Treatment non-adherence, for
Diabetes Ther (2016) 7:91–103 101
example, patients receiving but not filling AHA
prescriptions, also could be reason for the lack
of AHA claims since non-adherence is a known
issue in this population [14].
The results of this study are based on patients
whose data were captured in the linked
MarketScan Hospital Drug database, which
may not be generalizable to all individuals
with T2DM in the US. The hospitals that
contribute to the database are primarily
community hospitals and are
disproportionately located in the southern
region of the US. Most hospitals in which an
index admission occurred were non-teaching
hospitals (97%) and located in urban areas
(85%). AHA utilization patterns at teaching
hospitals or rural facilities could be different
than seen in our sample.
CONCLUSIONS
The results of this study suggest that a large
proportion of hospitalized patients with T2DM
may not receive optimal transitions of care in
and out of the hospital. Most patients (83%)
utilized an AHA while hospitalized but one-half
of all patients did not fill an AHA prescription
either in the 30 days before or 30 days after
hospitalization, and almost one-third of
patients did not fill an AHA prescription in the
90 days before or after hospitalization. One-fifth
of patients for whom T2DM is listed on a claim
associated with their inpatient care had no
evidence of being treated for diabetes before
their admission, suggesting they may have been
newly diagnosed at the time of admission and
would not have become aware of their T2DM at
that time if not for the hospitalization.
Under-diagnosis of T2DM and inadequate
treatment of diagnosed T2DM remains an
issue in and out of the hospital; when patients
are hospitalized, it is crucial to take advantage
of this opportunity to appraise and optimize
their care.
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